Autoimmune CD8+ T cells in type 1 diabetes: from single-cell RNA sequencing to T-cell receptor redirection

Area of Science:

• Immunology
• Endocrinology
• Genetics

Background:

• Type 1 diabetes (T1D) is an autoimmune disease characterized by pancreatic beta cell destruction, primarily mediated by autoreactive CD8+ T cells.
• A small population of stem cell-like beta cell-specific CD8+ T cells can induce T1D in normal mice, suggesting therapeutic potential in modulating these cells.
• The complex roles of different CD8+ T cell subsets (stem cell-type, effector, exhausted) and the diversity of T-cell receptors (TCRs) present challenges for precise T1D therapies.

Purpose of the Study:

• To review the mechanisms of autoimmune CD8+ T cells and TCRs in T1D pathogenesis.
• To explore the application of advanced technologies such as single-cell RNA sequencing (ScRNA-Seq), CRISPR/Cas9, chimeric antigen receptor T-cell (CAR-T), and T-cell receptor-gene engineered T cells (TCR-T) in the context of T1D.
• To provide a comprehensive overview of potential therapeutic strategies targeting CD8+ T cells and TCRs for T1D.

Main Methods:

• Literature review focusing on autoimmune CD8+ T cell and TCR mechanisms in T1D.
• Analysis of studies utilizing ScRNA-Seq for T1D research.
• Examination of gene-editing (CRISPR/Cas9) and T-cell engineering (CAR-T, TCR-T) approaches relevant to T1D.

Main Results:

• Autoreactive CD8+ T cells and their TCRs are central to T1D pathogenesis.
• Diverse CD8+ T cell populations and TCRs complicate targeted therapeutic development.
• Emerging technologies offer new avenues for understanding and potentially treating T1D by manipulating T cells.

Conclusions:

• Targeting CD8+ T cells and their TCRs represents a promising strategy for T1D prediction and treatment.
• Advanced single-cell and gene-editing technologies are crucial for dissecting T1D complexity and developing novel therapies.
• Further research into T-cell modulation holds significant potential for managing or curing T1D.